Reconstitution of T Cell Proliferation under Arginine Limitation: Activated Human T Cells Take Up Citrulline via L-Type Amino Acid Transporter 1 and Use It to Regenerate Arginine after Induction of Argininosuccinate Synthase Expression

Abstract

In the tumor microenvironment, arginine is metabolized by arginase-expressing myeloid cells. This arginine depletion profoundly inhibits T cell functions and is crucially involved in tumor-induced immunosuppression. Reconstitution of adaptive immune functions in the context of arginase-mediated tumor immune escape is a promising therapeutic strategy to boost the immunological antitumor response. Arginine can be recycled in certain mammalian tissues from citrulline via argininosuccinate (ASA) in a two-step enzymatic process involving the enzymes argininosuccinate synthase (ASS) and argininosuccinate lyase (ASL). Here, we demonstrate that anti-CD3/anti-CD28-activated human primary CD4+ and CD8+ T cells upregulate ASS expression in response to low extracellular arginine concentrations, while ASL is expressed constitutively. ASS expression peaked under moderate arginine restriction (20 µM), but no relevant induction was detectable in the complete absence of extracellular arginine. The upregulated ASS correlated with a reconstitution of T cell proliferation upon supplementation of citrulline, while the suppressed production of IFN-γ was refractory to citrulline substitution. In contrast, ASA reconstituted proliferation and cytokine synthesis even in the complete absence of arginine. By direct quantification of intracellular metabolites we show that activated primary human T cells import citrulline but only metabolize it further to ASA and arginine when ASS is expressed in the context of low amounts of extracellular arginine. We then clarify that citrulline transport is largely mediated by the L-type amino acid transporter 1 (LAT1), induced upon human T cell activation. Upon siRNA-mediated knockdown of LAT1, activated T cells lost the ability to import citrulline. These data underline the potential of citrulline substitution as a promising pharmacological way to treat immunosuppression in settings of arginine deprivation.

l-Arginine Synthesis from l-Citrulline in Myeloid Cells Drives Host Defense against Mycobacteria In Vivo

“…Yet if L-ARG synthesis is necessary in other cells, its loss in nonmyeloid populations does not alter mycobacterial burden in the lung (i.e., comparing deletion by Lyz2 cre/cre to Tie2cre) at the 8-wk end point of these studies. Regardless, with the known importance of L-ARG synthesis in endothelial cells (21,22,34,35) and T cells (17,18,(36)(37)(38), further investigation into how L-CIT metabolism affects these and other cell populations during infection warrants investigation. Considering the fluctuation of L-CIT in the lung (Fig.…”

Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities

“…The stiff ECM together with tumor metabolic state create a physical acidic, hypoxia [61] local environment filled with polyamines produced via activated arginase pathway [62,63]. This shelter the tumor antigen from immune surveillance, trap the cytotoxic T cells from infiltrating into tumor [64], and promote type 2 tumor-associated macrophage polarization and Treg activation [65,66].…”

The Trans-omics Landscape of COVID-19

“…Moreover, Larginine is important for T-cell proliferation and function. The release of Arginase (ARG1/2) from activated neutrophils inhibit T-cell activation by inducing L-Arginine and Glutamine depletion 51 . Here we found ARG1 and ARG2 levels were upregulated in critical patients.…”